Pharma giant Novo Nordisk to reveal booming demand for its weight loss drugs Ozempic and Wegovy

Boost: Celebrity fans include actress Rebel Wilson

Pharma giant Novo Nordisk will reveal the booming demand for its weight loss drugs this week.

The Danish firm’s revenues have surged thanks to an explosion in popularity for its diabetes and obesity drugs Ozempic and Wegovy.

Analysts estimate it will report sales of £7.7billion between April and June on Wednesday. They were £3.9billion for the same quarter last year. 

Wegovy is an injection that tricks the body into thinking it is full. It is available on the NHS but is particularly popular in the US. Celebrity fans include actress Rebel Wilson.

Novo Nordisk is now worth £210billion. 

Shares have risen 64 per cent over the past year.

DIY INVESTING PLATFORMS

Easy investing and ready-made portfolios

AJ Bell

Easy investing and ready-made portfolios

AJ Bell

Easy investing and ready-made portfolios

Free fund dealing and investment ideas

Hargreaves Lansdown

Free fund dealing and investment ideas

Hargreaves Lansdown

Free fund dealing and investment ideas

Flat-fee investing from £4.99 per month

interactive investor

Flat-fee investing from £4.99 per month

interactive investor

Flat-fee investing from £4.99 per month

Get £200 back in trading fees

Saxo

Get £200 back in trading fees

Saxo

Get £200 back in trading fees

Free dealing and no account fee

Trading 212

Free dealing and no account fee

Trading 212

Free dealing and no account fee

Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.

Compare the best investing account for you

***
Read more at DailyMail.co.uk